US5614492A
(en)
*
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
US6849708B1
(en)
|
1986-05-05 |
2005-02-01 |
The General Hospital Corporation |
Insulinotropic hormone and uses thereof
|
US7138486B2
(en)
|
1986-05-05 |
2006-11-21 |
The General Hospital Corporation |
Insulinotropic hormone derivatives and uses thereof
|
US5846747A
(en)
*
|
1992-03-25 |
1998-12-08 |
Novo Nordisk A/S |
Method for detecting glucagon-like peptide-1 antagonists and agonists
|
DK39892D0
(en)
*
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
PEPTIDE
|
SK155694A3
(en)
*
|
1992-06-15 |
1995-05-10 |
Pfizer |
Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
|
WO1994005789A1
(en)
*
|
1992-08-28 |
1994-03-17 |
Zymogenetics, Inc. |
Glucagon receptors
|
US6284727B1
(en)
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
CA2168448A1
(en)
*
|
1993-08-09 |
1995-02-16 |
Michael P. Graziano |
Human glucagon-like 1 peptide receptor
|
GB9502830D0
(en)
*
|
1995-02-14 |
1995-04-05 |
Ecole Polytech |
Regulation of polypeptide production in cells
|
DE69737561T2
(en)
*
|
1996-12-13 |
2008-03-06 |
Nps Allelix Corp., Toronto |
CLONED GLUCAGON-SIMILAR PEPTIDE-2 RECEPTORS
|
US8592553B2
(en)
|
1996-12-13 |
2013-11-26 |
Nps Pharmaceuticals, Inc. |
Cloned glucagon-like peptide-2 receptors
|
WO2000007617A1
(en)
|
1998-07-31 |
2000-02-17 |
Novo Nordisk A/S |
Use of glp-1 and analogues for preventing type ii diabetes
|
JP2002528721A
(en)
*
|
1998-10-23 |
2002-09-03 |
グラクソ グループ リミテッド |
Assays for nuclear receptor ligands
|
JP2003525908A
(en)
|
2000-03-08 |
2003-09-02 |
ノボ ノルディスク アクティーゼルスカブ |
Low serum lipids
|
US6448045B1
(en)
*
|
2000-03-10 |
2002-09-10 |
The Regents Of The University Of California |
Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1
|
US20020123071A1
(en)
*
|
2000-12-04 |
2002-09-05 |
Knudsen Sanne Moller |
Method of identifying compounds capable of acting as agonists or antagonists of G-protein coupled receptors
|
US6642003B2
(en)
|
2001-08-02 |
2003-11-04 |
Cedars-Sinai Medical Center |
Human glucose-dependent insulin-secreting cell line
|
DE60230818D1
(en)
|
2001-09-24 |
2009-02-26 |
Imp Innovations Ltd |
PYY3-36 FOR REDUCING OR PREVENTING GREASE LUBRICITY
|
US6911324B2
(en)
|
2001-10-18 |
2005-06-28 |
The Regents Of The University Of California |
Induction of beta cell differentiation in human cells
|
EP1474163A2
(en)
|
2002-01-10 |
2004-11-10 |
Imperial College Innovations Limited |
Modification of feeding behavior
|
US7141240B2
(en)
*
|
2002-03-12 |
2006-11-28 |
Cedars-Sinai Medical Center |
Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
|
DE60327771D1
(en)
|
2002-07-04 |
2009-07-09 |
Zealand Pharma As |
GLP-1 AND TREATMENT METHOD FOR DIABETES
|
EP1546200A2
(en)
|
2002-10-02 |
2005-06-29 |
Zealand Pharma A/S |
Stabilized exendin-4 compounds
|
US20040209803A1
(en)
*
|
2002-12-19 |
2004-10-21 |
Alain Baron |
Compositions for the treatment and prevention of nephropathy
|
US7790681B2
(en)
*
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
WO2004071393A2
(en)
*
|
2003-02-13 |
2004-08-26 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with glucagon-like peptide 1 receptor (glp1r)
|
WO2005018536A2
(en)
*
|
2003-05-23 |
2005-03-03 |
Human Genome Sciences, Inc. |
Agonist antibodies that specifically bind the glucagon like peptide-1 receptor
|
CN104826116A
(en)
|
2003-11-20 |
2015-08-12 |
诺沃挪第克公司 |
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
|
EP1694356B1
(en)
|
2003-12-09 |
2011-02-16 |
Novo Nordisk A/S |
Regulation of food preference using glp-1 agonists
|
CN1950078A
(en)
|
2004-06-11 |
2007-04-18 |
诺和诺德公司 |
Counteracting drug-induced obesity using glp-1 agonists
|
SG156683A1
(en)
|
2005-06-07 |
2009-11-26 |
Univ Rockefeller |
STIMULATION OF PANCREATIC β CELL PROLIFERATION
|
TWI428346B
(en)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
WO2009126709A1
(en)
*
|
2008-04-09 |
2009-10-15 |
Transtech Pharma, Inc. |
Ligands for the glp-1 receptor and methods for discovery thereof
|
WO2010043566A2
(en)
|
2008-10-17 |
2010-04-22 |
Sanofi-Aventis Deutschland Gmbh |
Combination of an insulin and a glp-1 agonist
|
ES2855146T3
(en)
|
2009-11-13 |
2021-09-23 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
|
US9707176B2
(en)
|
2009-11-13 |
2017-07-18 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a GLP-1 agonist and methionine
|
WO2011123943A1
(en)
|
2010-04-09 |
2011-10-13 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
MX343360B
(en)
|
2010-04-27 |
2016-11-03 |
Zealand Pharma As |
Peptide conjugates of glp-1 receptor agonists and gastrin and their use.
|
PT2611458T
(en)
|
2010-08-30 |
2016-12-16 |
Sanofi Aventis Deutschland |
Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
|
RU2600440C3
(en)
|
2010-12-16 |
2021-12-10 |
Ново Нордиск А/С |
SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N- (8- (2-HYDROXYBENZOYL) AMINO) CAPRYLIC ACID SALT
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
PT2750699E
(en)
|
2011-08-29 |
2015-11-03 |
Sanofi Aventis Deutschland |
Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
CN104144704B
(en)
|
2011-11-03 |
2018-03-23 |
西兰制药公司 |
The receptor agonist peptides gastrin conjugates of GLP 1
|
WO2013083826A2
(en)
|
2011-12-09 |
2013-06-13 |
Novo Nordisk A/S |
Glp-1 agonists
|
HRP20231613T1
(en)
|
2012-03-22 |
2024-03-15 |
Novo Nordisk A/S |
Compositions comprising a delivery agent and preparation thereof
|
US10933120B2
(en)
|
2012-03-22 |
2021-03-02 |
Novo Nordisk A/S |
Compositions of GLP-1 peptides and preparation thereof
|
MX366405B
(en)
|
2012-07-01 |
2019-07-08 |
Novo Nordisk As |
Use of long-acting glp-1 peptides.
|
AR091866A1
(en)
|
2012-07-23 |
2015-03-04 |
Zealand Pharma As |
GLUCAGON ANALOGS
|
TWI608013B
(en)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
Glucagon analogues
|
EP2908844A1
(en)
|
2012-10-17 |
2015-08-26 |
Novo Nordisk A/S |
Fatty acid acylated amino acids for oral peptide delivery
|
TWI780236B
(en)
|
2013-02-04 |
2022-10-11 |
法商賽諾菲公司 |
Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
UA122767C2
(en)
|
2013-10-17 |
2021-01-06 |
Зіленд Фарма А/С |
Acylated glucagon analogues
|
EA035688B1
(en)
|
2013-11-06 |
2020-07-27 |
Зилэнд Фарма А/С |
Glucagon-glp-1-gip triple agonist compounds
|
CA2929459C
(en)
|
2013-11-06 |
2022-05-03 |
Zealand Pharma A/S |
Gip-glp-1 dual agonist compounds and methods
|
CN112957455A
(en)
|
2014-01-09 |
2021-06-15 |
赛诺菲 |
Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
SG11201604706TA
(en)
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized pharmaceutical formulations of insulin aspart
|
WO2015104311A1
(en)
|
2014-01-09 |
2015-07-16 |
Sanofi |
Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
EP3006045B3
(en)
|
2014-10-07 |
2021-03-17 |
Cyprumed GmbH |
Pharmaceutical formulations for the oral delivery of peptide or protein drugs
|
BR112017008659A2
(en)
|
2014-10-29 |
2018-01-30 |
Zealand Pharma As |
? gip agonist methods and compounds?
|
CN107206058A
(en)
|
2014-12-12 |
2017-09-26 |
赛诺菲-安万特德国有限公司 |
Insulin glargine/lixisenatide fixed ratio preparaton
|
TWI748945B
(en)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
Treatment type 2 diabetes mellitus patients
|
TW201705975A
(en)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
Treatment of type 2 diabetes mellitus patients
|
AU2016247499B2
(en)
|
2015-04-16 |
2020-09-03 |
Zealand Pharma A/S |
Acylated glucagon analogue
|
CA2997343A1
(en)
|
2015-10-07 |
2017-04-13 |
Cyprumed Gmbh |
Pharmaceutical formulations for the oral delivery of peptide drugs
|
WO2018065634A1
(en)
|
2016-10-07 |
2018-04-12 |
Cyprumed Gmbh |
Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
|
CN117384274A
(en)
|
2016-12-09 |
2024-01-12 |
西兰制药公司 |
Acylated GLP-1/GLP-2 dual agonists
|
TWI762706B
(en)
|
2017-08-24 |
2022-05-01 |
丹麥商諾佛 儂迪克股份有限公司 |
Glp-1 compositions and uses thereof
|
EP3746111B1
(en)
|
2018-02-02 |
2023-07-19 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
|
US20210087250A1
(en)
|
2018-04-06 |
2021-03-25 |
Cyprumed Gmbh |
Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
|
TWI829687B
(en)
|
2018-05-07 |
2024-01-21 |
丹麥商諾佛 儂迪克股份有限公司 |
Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
CN111423506B
(en)
*
|
2019-11-08 |
2023-06-27 |
成都奥达生物科技有限公司 |
GLP-1 compound
|
WO2021144476A1
(en)
|
2020-02-18 |
2021-07-22 |
Novo Nordisk A/S |
Pharmaceutical formulations
|
US11478533B2
(en)
|
2020-04-27 |
2022-10-25 |
Novo Nordisk A/S |
Semaglutide for use in medicine
|
CN115461044A
(en)
|
2020-04-29 |
2022-12-09 |
诺和诺德股份有限公司 |
Solid compositions comprising a GLP-1 agonist and histidine
|
WO2022049310A1
(en)
|
2020-09-07 |
2022-03-10 |
Cyprumed Gmbh |
Improved pharmaceutical formulations of glp-1 receptor agonists
|
WO2023012263A1
(en)
|
2021-08-04 |
2023-02-09 |
Novo Nordisk A/S |
Solid oral peptide formulations
|